Processa Pharmaceuticals, Inc.

The momentum for this stock is not very good. Processa Pharmaceuticals, Inc. is not very popular among insiders. Tradey thinks it is not wise to invest in Processa Pharmaceuticals, Inc..

News

Processa Pharmaceuticals to Participate in Investor and Industry Conferences During September

Globe Newswire HANOVER, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) announces that management will be participating in the following investor and industry conferences...\n more…

Processa Pharmaceuticals reports Q2 EPS ($1.01) vs. ($1.94) last year

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Processa Pharmaceuticals Provides Product Pipeline and Financial Update

Globe Newswire Phase 2 trial with NGC-Cap in breast cancer underway NGC-Cap Phase 1b trial demonstrated a favorable safety profile with preliminary anti-tumor activity Preclinical studies demonstrated NGC-Iri...\n more…

Processa Pharmaceuticals, Inc. Expected to Post Q3 2024 Earnings of ($1.00) Per Share (NASDAQ:PCSA)

Ticker Report Processa Pharmaceuticals, Inc. (NASDAQ:PCSA - Free Report) - Equities research analysts at HC Wainwright raised their Q3 2024 earnings estimates for shares of Processa Pharmaceuticals in a research...\n more…

Processa Pharmaceuticals (NASDAQ:PCSA) Price Target Lowered to $6.00 at HC Wainwright

Ticker Report Processa Pharmaceuticals (NASDAQ:PCSA - Free Report) had its price objective reduced by HC Wainwright from $8.00 to $6.00 in a research report sent to investors on Monday, Benzinga reports. HC...\n more…